

TMS TRENDS

FEBRUARY 2014

A publication of the TMS Institute of Pennsylvania – Advanced Neuropsychiatric Solutions



[HTTP://WWW.FLICKR.COM/PHOTOS/ZIONFICTION/7484820084/IN/PHOTOSTREAM/](http://www.flickr.com/photos/zionfiction/7484820084/in/photostream/)

GLOBAL TMS GROWTH: MIGRAINES IN BRITAIN

Last month, Britain's National Institute for Health and Care Excellence (NICE) approved the use of transcranial magnetic stimulation (TMS) for the treatment and prevention of acute migraines.

Clinical trials have shown that, after a single treatment, more than a third of patients were free of pain immediately following the treatment. Additionally, more than three-fourths of patients who received consecutive treatments of TMS experienced a decrease in frequency of migraine attacks. Due to the wealth of scientific evidence supporting its efficacy, specialist-administered TMS will now be available to patients in the UK suffering from migraines, many of whom have not responded to previous treatments.

Although TMS is not currently approved for the treatment of migraines in the US, this overseas development demonstrates its increasingly recognized efficacy as a treatment modality beyond its use for depression. We at the TMS Institute of Pennsylvania excitedly anticipate further studies which highlight the safety and efficacy of this fascinating technology for treatment of other neuropsychiatric, neuromuscular, and pain disorders, in addition to the spectrum of other mental health disorders.

TIME FOR A QUIZ! TRUE OR FALSE:

1. ECT was developed in Ireland in the late 1930's.
2. TMS was first developed in the US.
3. TMS has now been in use for approximately 30 years.
4. Neurostar TMS Therapy is the first and only FDA-approved TMS device for treating refractory depression.
5. Seizures are experienced frequently in TMS Therapy.
6. In treating depression, TMS Therapy consists of 4-6 weeks of daily (M-F) sessions lasting about 37 minutes each.
7. TMS Therapy is a non-systemic, non-invasive option for treatment-resistant depression that can be performed in an outpatient setting.
8. Patients undergoing TMS Therapy may experience headache or pain at the site of stimulation.
9. According to a recent study of those who responded favorably to TMS, remission rates one year later approach 70%.

Answers

- | | | | |
|----------|----------|---------|----------|
| 1. false | 2. false | 3. true | 4. false |
| 5. false | 6. true | 7. true | 8. true |
| 9. true | | | |